Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-WHEN: Tenecteplase in Acute Ischemic Stroke
NCT06320431Phase 3Recruiting
- Sponsor
- University of Calgary
- Start
- Sep 2024
- Primary completion
- Sep 2030
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (3 arms), sponsored by University of Calgary. Primary endpoint: Modified Rankin Scale at 90 days. Started Sep 2024; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06320431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06320431.